Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders.

Darcy A KruegerAnjali SadhwaniAnna W ByarsPetrus J de VriesDavid N FranzVicky H WhittemoreRajna Filip-DhimaDonna MurrayKush KapurMustafa Sahin

Published in: Annals of clinical and translational neurology (2017)

While safe, oral everolimus administered once daily for 6 months did not significantly improve neurocognitive functioning or behavior in children with TSC.

Keyphrases

young adults
physical activity
replacement therapy
temporal lobe epilepsy